This heightened state can delay sleep onset, reduce REM sleep duration, and trigger middle-of-the-night awakenings
Label expansion: as the label for these GLP1s+ expand, it will naturally extend to already covered disease states (e.g., cardiovascular disease (CVD) for Medicare)
Understanding which situation applies requires looking at both clinical response over time and the genetic variants that shape the relevant pathways
For patients with obesity and comorbidities (type 2 diabetes, hypertension, sleep apnea), referral to obesity medicine specialists or registered dietitians is appropriate for comprehensive management
Biol Reprod (2016) 94(6):127
Dosage requirements typically increase over timetwo units for 4-8 weeks, three units for 8-12 weeks, and four units for treatments exceeding 12 weeks